Novo Nordisk surges on plan to resubmit rejected insulin in U.S.

March 27, 2015 8:28 AM

5 0

(Reuters) - Denmark's Novo Nordisk is to resubmit its new insulin Tresiba to U.S. regulators based on interim analysis data from a clinical trial, bringing its biggest new drug hope closer to the world's top market.

Shares in the company leapt 13 percent to an all-time high in early trade in Copenhagen on Friday after it said it would file with the U.S. Food and Drugs Administration (FDA) within the next month. The drug was rebuffed by the FDA two years ago.

Also read: China issues $722 bln in new mortgages to individuals in 2016

Read more

To category page